AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03585374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a dose of 0.10 mg/Kg body weight. The time of infusion should be not longer than 10 minutes.
Study NCT03585374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 1 g dose The time of infusion should be not longer than 10 minutes.
Study NCT03585374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen
Description: Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 100 mg dose. The time of infusion should be not longer than 10 minutes.
Study NCT02950662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overdenture
Description: Active comparator will be metal housing and peek housing
Study NCT01208896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced_intensity conditioning
Description: The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
Study NCT00510588 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: training
Description: regular physical exercise training for 6 months
Study NCT00510588 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: training + metformin
Description: regular physical exercise training in combination with metformin for 6 months
Study NCT00510588 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: training + glitazon
Description: regular physical exercise training in combination with a glitazon for 6 months
Study NCT03127241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Assistive device (Armon Ayura) test
Description: Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported.
Study NCT03127241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Assistive device (Jaeco Wrex) test
Description: Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported.
Study NCT02441985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim RapidStim2
Description: Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
Study NCT02441985 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Magstim RapidStim2
Description: Same procedure as real rTMS without stimulating the cerebral cortex.
Study NCT03873129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile health app (mHealth)
Description: A-CHESS is a mobile health app for participants to interact with their treatment team for 12 months.
Study NCT02188121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors
Study NCT02188121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Angiotensin II receptor antagonist
Study NCT02441985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fahn-Tolosa-Marin Tremor Rating Scale (TRS)
Description: All participants will receive a clinical assessment of tremor severity by using the TRS test.
Study NCT02441985 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Fahn-Tolosa-Marin Tremor Rating Scale (TRS)
Description: All participants will receive a clinical assessment of tremor severity by using the TRS test.
Study NCT02441985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timed Up & Go Test (TUG) test
Description: All participants will receive a clinical assessment of basic mobility skills by using the TUG test.
Study NCT02441985 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Timed Up & Go Test (TUG) test
Description: All participants will receive a clinical assessment of basic mobility skills by using the TUG test.
Study NCT02441985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10m walk test
Description: All participants will receive a clinical assessment of walking speed by using the walk test.
Study NCT02441985 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 10m walk test
Description: All participants will receive a clinical assessment of walking speed by using the walk test.
Study NCT02441985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tremor electrophysiology
Description: All participant tremors will by analyzed using an EMG system
Study NCT02441985 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Tremor electrophysiology
Description: All participant tremors will by analyzed using an EMG system
Study NCT02441985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebellar-brain Inhibition (CBI)
Description: All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
Study NCT02441985 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cerebellar-brain Inhibition (CBI)
Description: All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
Study NCT01984125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point-of-Care Prompt
Study NCT01448174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin (10 - 80 mg/day) will be administered orally in the one evening dose in the case of strict indications for such a treatment. Before starting atorvastatin, serum lipid profile will be examined two times, and when both results are abnormal the treatment is started. Duration of administration:~* atorvastatin 12 weeks, 6 weeks washout, placebo 12 weeks or~* placebo 12 weeks,6 weeks washout,atorvastatin 12 weeks.
Study NCT01682707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laryngoscopy
Description: tracheal intubation with two different techniques, track light and laryngoscopy.
Study NCT01682707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: track light
Study NCT01034761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pop-up alert
Description: Pop-up alert in the electronic medical record whenever the provider enters an order for a specified high risk medication from the Beers list.
Study NCT01155999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T1225
Description: one drop twice daily (morning and evening) in each eye from Day 0 to Day 2
Study NCT01155999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Description: 1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6
Study NCT02100618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples will be collected from all subjects at Year 6.5
Study NCT02100618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood samples will be collected from all subjects at Year 6.5
Study NCT02517333 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EPIC Club
Description: Weekly exercise gym sessions (1-2 times weekly) for 45-60 mins each session. Participants will start with a warm-up of 30 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. Gym sessions aim to involve bursts of high-intensity and monitoring of heart rate (potentially with wrist activity monitors with heart rate monitoring and accelerometers) to identify level of physical activity intensity. Participants will also have the opportunity to engage in 'Have a go' sports days run by the Oxfordshire Sports Partnership.
Study NCT03282175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
Study NCT03282175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Each training session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
Study NCT03282175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group did not receive any treatment.
Study NCT01901133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: Oral
Study NCT01668979 — intervention group
Intervention type: DEVICE
Intervention: new system to detect Near Falls
Description: We will invite healthy older adults with a history of falls to try the new system and assess whether the new system can induce, detect and quantify Near Fall episodes
Study NCT04223921 — intervention group
Intervention type: OTHER
Intervention: Comparison of patient's medicines
Description: Comparison of patient's medicines:~* between patient's discharge from hospital and one month after this discharge (acute geriatric care unit)~* between patient's admission and discharge from hospital (acute geriatric care unit
Study NCT01888718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine Hydrochloride
Description: Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg
Study NCT01888718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine Hydrochloride
Description: Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg
Study NCT00752570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 386
Description: AMG 386 (10 mg/kg QW) will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
Study NCT00752570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 386 Placebo
Description: AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
Study NCT00752570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.~FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.~FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest.
Study NCT00752570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFIRI
Description: Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.~FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.~FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest.
Study NCT03807505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus nerve block
Description: An interscalene brachial plexus nerve block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
Study NCT03807505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: An erector spinae plane block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
Study NCT01910558 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-cyclodextrin and digestible starch
Description: Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 3 gram alpha-cyclodextrin and 3 gram of starch
Study NCT01910558 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-cyclodextrin
Description: Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams alpha-cyclodextrin
Study NCT01910558 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Digestible starch
Description: Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams digestible starch
Study NCT03271619 — intervention group
Intervention type: OTHER
Intervention: Surface current measurement
Description: Measurement of surface current between electrodes placed on the chest wall during defibrillation
Study NCT04346303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Short-term Interactive Video Games
Description: 1. Collect basic information through a structured questionnaire, which includes basic information, disease status, life style and other related information.~2. Three data collections were performed, namely the baseline period (T0) and the pre-program (T1) two weeks later. Three weeks of intervention activities were provided twice a week, followed by a post-test ( post-program, T2).~3. After a total of six times mentioned above, each 60 minutes of interactive video game intervention, the patient completed the activity feedback form, reflecting the feelings and feedback of participating in the activity.
Study NCT03323151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib 3 mg by mouth on days 1, 8 and 15 by mouth days 1-28 of a 28 day cycle. Dose may be escalated (Ixazomib 4 mg) dependent on dose-limiting toxicities. Note: Ixazomib dose will not be de-escalated but remain at 3 mg.
Study NCT03323151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib 4 mg by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity.
Study NCT03323151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ibrutinib 420 mg) or escalated (Ibrutinib 560 mg) dependent on dose-limiting toxicities.
Study NCT03323151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity.
Study NCT01625039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Employee wellness programme
Description: The experimental group was subjected to a wellness programme based on the principles of cognitive behaviour therapy (CBT) as well as weekly supervised exercise classes over six weeks.
Study NCT01625039 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator (Once off educational session and educational materials)
Description: Once off educational session and educational materials
Study NCT01258218 — intervention group
Intervention type: DEVICE
Intervention: Implantation of an Accent MRI device
Description: Implantation of an Accent MRI device
Study NCT01397487 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blastomere biopsy
Description: The blastomere biopsy will be done after 72 hours of embryo culture. An inverted microscope Olympus IX70 with a heated stage will be used to perform the biopsy. The micromanipulation for the blastomere extraction will be made with a micropipette MBB-FP-M-30 (Humagen).
Study NCT04548154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proximal Resistance Training
Description: Participants will be prescribed 5 categories of resistance exercises, and each category will have a series of exercises to select from. Two will target hip abduction, two will target trunk muscles, and one will target functional resistance training for the hip and trunk during walking-related tasks such as multi-directional resisted walking. Dosing will be based on guidelines for MS. Strengthening exercises will begin with 3 sets of 12-15 reps at 15 rep-max load (RM) and progress to 3 sets of 8-10 reps at 10-12 RM. Endurance exercises requiring a static hold will progress from 3 sets of 15-20 second holds to 30-second holds. Functional resistance will be dosed to improve muscular endurance: 3 sets of 15-20 reps based on form fatigue.
Study NCT01667120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac 0.5mg/kg IV q8h x 72h.
Study NCT01667120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% normal saline 1ml/kg
Study NCT01283217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS
Description: Docetaxel with S-1. S-1: Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
Study NCT01283217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP
Description: S-1 with cisplatin. S-1 : Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
Study NCT01394991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 450 IU/kg once a week
Description: 450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Study NCT01394991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg 3 times a week
Description: 150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Study NCT01394991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 450 IU/kg once a week (QW)
Description: 450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
Study NCT01394991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg 3 times a week (TIW)
Description: 150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
Study NCT01031043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol
Description: Taking part in this research study is voluntary. Patient may choose not to take part in this research study or may withdraw consent at any time. Their choice will not at any time affect the commitment of the health care providers to administer care. If the patient decides not to participate or withdraw from the study there will be no penalty or loss of benefits to which they are otherwise entitled.
Study NCT03354299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coconut milk
Description: 50 cc of coconut milk supplementation plus 25 gram sugar (pudding) was given to cirrhosis patients as late night snack
Study NCT03354299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: coconut milk
Description: 50 cc of coconut milk supplementation plus 25 gram sugar (pudding) was given to cirrhosis patients as late night snack
Study NCT03524820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administration of drug
Study NCT03608020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMX-001
Description: Manganese butoxyethyl pyridyl porphyrin
Study NCT03608020 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain Radiation Therapy
Description: Whole Brain Radiation Therapy per standard of care.